[
  {
    "ts": null,
    "headline": "Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?",
    "summary": "Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
    "url": "https://finnhub.io/api/news?id=adc02c92bbe8acd41ae12b919a8e2548b9dea1ccd3fccaf1a9554f706966d934",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753200603,
      "headline": "Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?",
      "id": 136034016,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRL",
      "source": "Yahoo",
      "summary": "Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
      "url": "https://finnhub.io/api/news?id=adc02c92bbe8acd41ae12b919a8e2548b9dea1ccd3fccaf1a9554f706966d934"
    }
  },
  {
    "ts": null,
    "headline": "Why Are Charles River Laboratories (CRL) Shares Soaring Today",
    "summary": "Shares of lab services company Charles River Laboratories (NYSE:CRL) jumped 7.5% in the morning session after the company announced a plasmid DNA manufacturing agreement with Elly's Team, a parent-led foundation working to find a cure for a rare genetic disorder.",
    "url": "https://finnhub.io/api/news?id=16b569c1e18bc63fce5dc976c786487fa947c6916bfc94d223088e81bb032645",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753199793,
      "headline": "Why Are Charles River Laboratories (CRL) Shares Soaring Today",
      "id": 136034017,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRL",
      "source": "Yahoo",
      "summary": "Shares of lab services company Charles River Laboratories (NYSE:CRL) jumped 7.5% in the morning session after the company announced a plasmid DNA manufacturing agreement with Elly's Team, a parent-led foundation working to find a cure for a rare genetic disorder.",
      "url": "https://finnhub.io/api/news?id=16b569c1e18bc63fce5dc976c786487fa947c6916bfc94d223088e81bb032645"
    }
  },
  {
    "ts": null,
    "headline": "Oakmark U.S. Concentrated Strategy Q2 2025 Commentary",
    "summary": "Oakmark U.S. Concentrated Strategy Q2 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=4ee024e79694d768d4512b66aeda71115ba0774c11400d04cd9daf7430d603f6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753186800,
      "headline": "Oakmark U.S. Concentrated Strategy Q2 2025 Commentary",
      "id": 136032760,
      "image": "",
      "related": "CRL",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=4ee024e79694d768d4512b66aeda71115ba0774c11400d04cd9daf7430d603f6"
    }
  },
  {
    "ts": null,
    "headline": "Charles River Joins Elly’s Team to Drive Rare Disease Gene Therapy Development",
    "summary": "WILMINGTON, Mass., July 22, 2025--As part of Charles River’s Cell & Gene Therapy Accelerator Program, Elly’s Team manufactured critical starting materials for a Phase I clinical trial.",
    "url": "https://finnhub.io/api/news?id=d6ba1586dcbe00eae2a59631148796492f0f3995bc8ec677918d527f9d9ed66b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753185600,
      "headline": "Charles River Joins Elly’s Team to Drive Rare Disease Gene Therapy Development",
      "id": 136032401,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRL",
      "source": "Yahoo",
      "summary": "WILMINGTON, Mass., July 22, 2025--As part of Charles River’s Cell & Gene Therapy Accelerator Program, Elly’s Team manufactured critical starting materials for a Phase I clinical trial.",
      "url": "https://finnhub.io/api/news?id=d6ba1586dcbe00eae2a59631148796492f0f3995bc8ec677918d527f9d9ed66b"
    }
  }
]